Single nucleotide polymorphism array analysis to predict clinical outcome in neuroblastoma patients

Area of Science:

• Oncology
• Genetics
• Pediatric Cancer Research

Background:

• Neuroblastoma (NB) is a heterogeneous childhood cancer with variable outcomes.
• Japan implemented a nationwide NB mass screening (MS) for infants, potentially detecting most NB cases, including regressing tumors.

Purpose of the Study:

• To investigate the genetic heterogeneity of neuroblastoma (NB).
• To correlate genomewide genetic alterations with clinical outcomes in NB patients.

Main Methods:

• Genomic DNA was analyzed from 198 NB tissue and paired blood samples using single nucleotide polymorphism arrays.
• Cases included 76 from mass screening (MS) and others.

Main Results:

• Genetic aberrations were classified into four types: whole gain/loss, partial gain/loss, MYCN-amplified, and silent.
• Mass screening (MS)-detected NB predominantly showed the whole gain/loss type.
• Unfavorable outcomes were associated with partial gain/loss, MYCN-amplified, or silent genetic types.

Conclusions:

• Genomewide genetic analysis effectively predicts neuroblastoma (NB) patient outcomes.
• The whole gain/loss type may respond to current therapies, but other subtypes require different strategies.
• Further validation is needed to develop tools for predicting NB clinical outcomes.